Published in Antioxid Redox Signal on June 01, 2009
Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res (2011) 1.70
Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury. J Neurosci (2010) 1.38
Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Med Genomics (2011) 1.37
Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation (2009) 1.25
Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol (2010) 1.06
KLF11 mediates PPARγ cerebrovascular protection in ischaemic stroke. Brain (2013) 1.01
Vascular PPARδ protects against stroke-induced brain injury. Arterioscler Thromb Vasc Biol (2011) 1.01
Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ deletion promotes abdominal aortic aneurysms. J Vasc Surg (2010) 1.00
Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes. Antioxid Redox Signal (2011) 0.97
Hypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling. Am J Physiol Lung Cell Mol Physiol (2011) 0.93
Peroxisome proliferator-activated receptors for hypertension. World J Cardiol (2014) 0.92
Identifying plausible adverse drug reactions using knowledge extracted from the literature. J Biomed Inform (2014) 0.89
Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease. Clin Transl Sci (2011) 0.89
Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. PPAR Res (2015) 0.87
Peroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis. J Biol Chem (2011) 0.85
PPARδ agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling. Biomed Res Int (2013) 0.83
Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ mediates pioglitazone-reduced vascular lesion formation. Arterioscler Thromb Vasc Biol (2010) 0.82
Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway. J Biol Chem (2010) 0.81
Kinase-SUMO networks in diabetes-mediated cardiovascular disease. Metabolism (2016) 0.80
Evodiamine Attenuates PDGF-BB-Induced Migration of Rat Vascular Smooth Muscle Cells through Activating PPARγ. Int J Mol Sci (2015) 0.79
ω-6 lipids regulate PPAR turnover via reciprocal switch between PGC-1 alpha and ubiquitination. Atherosclerosis (2012) 0.79
Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors. PPAR Res (2014) 0.78
Anti-diabetic formulations of Nāga bhasma (lead calx): A brief review. Anc Sci Life (2013) 0.78
Interleukin-19 induces angiogenesis in the absence of hypoxia by direct and indirect immune mechanisms. Am J Physiol Cell Physiol (2016) 0.77
Transforming growth factor beta 1 induced endothelin-1 release is peroxisome proliferator-activated receptor gamma dependent in A549 cells. J Inflamm (Lond) (2016) 0.76
Vasotrophic regulation of age-dependent hypoxic cerebrovascular remodeling. Curr Vasc Pharmacol (2013) 0.76
Association of exposure to di-2-ethylhexylphthalate replacements with increased blood pressure in children and adolescents. Hypertension (2015) 0.76
Three-dimensional micro computed tomography analysis of the lung vasculature and differential adipose proteomics in the Sugen/hypoxia rat model of pulmonary arterial hypertension. Pulm Circ (2016) 0.75
Isoliquiritigenin Attenuates Atherogenesis in Apolipoprotein E-Deficient Mice. Int J Mol Sci (2016) 0.75
Nelfinavir suppresses insulin signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J (2013) 0.75
Hypaphorine Attenuates Lipopolysaccharide-Induced Endothelial Inflammation via Regulation of TLR4 and PPAR-γ Dependent on PI3K/Akt/mTOR Signal Pathway. Int J Mol Sci (2017) 0.75
FGF1 - a new weapon to control type 2 diabetes mellitus. Nat Rev Endocrinol (2017) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
The steroid and thyroid hormone receptor superfamily. Science (1988) 25.68
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 13.34
Diabetes and cardiovascular disease. The Framingham study. JAMA (1979) 11.95
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 11.92
Atherosclerosis. the road ahead. Cell (2001) 11.88
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 11.72
G1 phase progression: cycling on cue. Cell (1994) 11.62
Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature (2007) 11.59
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 10.09
PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell (1999) 10.08
Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev (1999) 9.94
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell (1995) 7.99
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell (1998) 7.91
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA (2003) 7.35
PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab (2007) 7.19
Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol (1995) 7.12
Drug-induced hepatotoxicity. N Engl J Med (2003) 7.11
Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest (1999) 6.99
New functional activities for the p21 family of CDK inhibitors. Genes Dev (1997) 6.97
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature (2005) 6.83
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (1992) 6.69
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell (2003) 6.53
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
AMPK and PPARdelta agonists are exercise mimetics. Cell (2008) 6.39
PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med (2001) 6.09
Biological action of leptin as an angiogenic factor. Science (1998) 6.02
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature (2000) 5.86
Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab (2008) 5.83
CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem (1993) 5.81
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell (1998) 5.78
A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell (2001) 5.76
Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol (2004) 5.66
Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J (1995) 5.59
Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab (2008) 5.53
The PPARalpha-leukotriene B4 pathway to inflammation control. Nature (1996) 5.14
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2000) 5.07
Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell (1992) 4.95
A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A (1999) 4.91
Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest (2007) 4.86
Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol (1997) 4.71
Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology (1994) 4.67
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature (2000) 4.66
Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A (1993) 4.56
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science (1996) 4.50
Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A (1992) 4.38
Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol (2003) 4.35
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell (2007) 4.33
Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature (1999) 4.32
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell (1999) 4.32
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell (2005) 4.30
The many forks in FOXO's road. Sci STKE (2003) 4.23
The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest (2002) 4.22
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A (2001) 4.22
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol (1994) 4.15
Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol (2004) 4.05
Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science (2003) 3.97
The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J (1992) 3.92
15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A (2000) 3.89
Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol (2005) 3.84
Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation (2002) 3.65
Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A (2001) 3.58
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation (2005) 3.54
Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab (2005) 3.49
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (1998) 3.48
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol (2000) 3.37
PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2006) 3.29
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem (1998) 3.27
Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest (2004) 3.23
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem (1997) 3.19
Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature (2002) 3.11
Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A (2005) 3.03
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry (2002) 2.97
Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A (1998) 2.93
Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell (1999) 2.92
Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev (1998) 2.89
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2001) 2.85
The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med (2001) 2.81
Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J (2003) 2.80
Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem (2005) 2.79
A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A (2003) 2.68
Leptin, the product of Ob gene, promotes angiogenesis. Circ Res (1998) 2.63
Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med (2004) 2.61
Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res (2003) 2.58
Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab (2003) 2.51
A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J Clin Invest (1998) 2.42
Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A (2005) 3.03
Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology (2006) 2.95
Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation (2009) 2.83
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
Neuroendocrine and neuroimmune markers in IBS: pathophysiological role or epiphenomenon? Gastroenterology (2006) 2.68
Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain (2005) 2.51
Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology (2008) 2.39
Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology (2003) 2.32
Nitrated fatty acids: Endogenous anti-inflammatory signaling mediators. J Biol Chem (2006) 2.31
The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis. EMBO J (2011) 2.08
Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol (2010) 2.02
Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun (2004) 1.98
Klotho is a target gene of PPAR-gamma. Kidney Int (2008) 1.96
miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia. Neurobiol Dis (2010) 1.89
Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc (2005) 1.88
Generation of PPARγ mono-allelic knockout pigs via zinc-finger nucleases and nuclear transfer cloning. Cell Res (2011) 1.74
Nitro-linoleic acid inhibits vascular smooth muscle cell proliferation via the Keap1/Nrf2 signaling pathway. Am J Physiol Heart Circ Physiol (2007) 1.70
Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol (2008) 1.67
The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med (2007) 1.65
Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J (2008) 1.63
A comparison of visceral and somatic pain processing in the human brainstem using functional magnetic resonance imaging. J Neurosci (2005) 1.60
Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem (2010) 1.57
An entropy-based approach for testing genetic epistasis underlying complex diseases. J Theor Biol (2007) 1.56
Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol (2005) 1.52
Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med (2004) 1.51
Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol (2003) 1.50
Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. J Mol Cell Biol (2014) 1.41
Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. J Psychosom Res (2003) 1.40
Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury. J Neurosci (2010) 1.38
Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene (2003) 1.37
Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol (2008) 1.35
Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol (2011) 1.35
Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res (2010) 1.34
Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology (2009) 1.33
Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation (2009) 1.30
Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation (2012) 1.30
Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med (2009) 1.28
The effect of life stress on symptoms of heartburn. Psychosom Med (2004) 1.28
Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation (2009) 1.25
MicroRNA-1 regulates smooth muscle cell differentiation by repressing Kruppel-like factor 4. Stem Cells Dev (2010) 1.24
Sex-based differences in gastrointestinal pain. Eur J Pain (2004) 1.23
miR-10a contributes to retinoid acid-induced smooth muscle cell differentiation. J Biol Chem (2010) 1.21
A highly efficient method to differentiate smooth muscle cells from human embryonic stem cells. Arterioscler Thromb Vasc Biol (2007) 1.20
Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia. J Biol Chem (2012) 1.19
Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21. Endocrinology (2014) 1.18
Nitroalkenes suppress lipopolysaccharide-induced signal transducer and activator of transcription signaling in macrophages: a critical role of mitogen-activated protein kinase phosphatase 1. Endocrinology (2008) 1.16
Expression profiling of nuclear receptors in human and mouse embryonic stem cells. Mol Endocrinol (2009) 1.16
Toll-like receptor-mediated IRE1α activation as a therapeutic target for inflammatory arthritis. EMBO J (2013) 1.15
Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology (2008) 1.14
Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response. J Biol Chem (2009) 1.14
Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol (2010) 1.14
Nitro-fatty acid inhibition of neointima formation after endoluminal vessel injury. Circ Res (2009) 1.13
Generation of an adult smooth muscle cell-targeted Cre recombinase mouse model. Arterioscler Thromb Vasc Biol (2006) 1.11
Rad as a novel regulator of excitation-contraction coupling and beta-adrenergic signaling in heart. Circ Res (2009) 1.11
A comparison of murine smooth muscle cells generated from embryonic versus induced pluripotent stem cells. Stem Cells Dev (2009) 1.09
Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am (2007) 1.09
Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol (2011) 1.09
Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. Am J Gastroenterol (2002) 1.08
Monocyte chemotactic protein-induced protein 1 (MCPIP1) suppresses stress granule formation and determines apoptosis under stress. J Biol Chem (2011) 1.07
Rad GTPase attenuates vascular lesion formation by inhibition of vascular smooth muscle cell migration. Circulation (2005) 1.06
Smooth and cardiac muscle-selective knock-out of Kruppel-like factor 4 causes postnatal death and growth retardation. J Biol Chem (2010) 1.06
MicroRNA-27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mitochondrial function in human adipose-derived stem cells. J Biol Chem (2013) 1.05
Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology (2002) 1.05
PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) (2009) 1.03
Porous nanofibrous PLLA scaffolds for vascular tissue engineering. Biomaterials (2010) 1.03
Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol (2012) 1.03
Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. Eur J Gastroenterol Hepatol (2005) 1.02
Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells. Arterioscler Thromb Vasc Biol (2008) 1.02
Electrophilic nitro-fatty acids inhibit vascular inflammation by disrupting LPS-dependent TLR4 signalling in lipid rafts. Cardiovasc Res (2013) 1.01
KLF11 mediates PPARγ cerebrovascular protection in ischaemic stroke. Brain (2013) 1.01
Increased acoustic startle responses in IBS patients during abdominal and nonabdominal threat. Psychosom Med (2008) 1.01
Gene expression module-based chemical function similarity search. Nucleic Acids Res (2008) 1.01
Vascular PPARδ protects against stroke-induced brain injury. Arterioscler Thromb Vasc Biol (2011) 1.01